Physician profile
James M Jackson
NPI 1285697466
$4,623.63
in general payments reported to CMS, 2019-2025
37 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $156 · 2021: $108 · 2022: $516 · 2023: $851 · 2024: $905 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Education: $17.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.74 |
| Education | $17.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $640.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $572.04 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $422.21 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.27 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $322.53 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $281.13 | 2019-2022 | |
| Novo Nordisk INC | $255.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $231.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $163.52 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $135.36 | 2019-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $119.51 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $110.33 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $101.46 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $90.25 | 2019-2024 | |
| Daiichi Sankyo INC. | $89.81 | 2019-2023 | Injectafer |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.